Sign In   |   Register


Breaking News:

Breaking News

3-11-19 Canbiola, Inc. (CANB) Canbiola is Registered and Active in the GSA’s System for Award Management (SAM) and Department of Defense (DOD)
Read Complete Press Release>>

Trickle Research issues update of
AzurRx Biopharma, Inc.  2-26-19
12-24 Month Price Target $10.25

Click Here for Update Report

Trickle Research Earnings Update 2-9-19
  Social Reality Inc. (SRAX)
12-24 Month Target Price $9.25

Click Here for Report

1-28-19 Clean Coal Technologies ( CCTC)

 “Game Changer” technology for the $50 billion coal market?
Click Here for complete Interview and Article

1-22-19 New Jersey Mining Company (NJMC)
New Jersey Mining Company intercepts high-grade gold mineralization in the Paymaster Shoot

Read Complete Press Release>>

1-15-19 Canbiola, Inc. (CANB)
Senator Ronald A. Silver Joins Canbiola, Inc. Corporate Advisory Board

Read Complete Press Release>>

Greenridge Global Equity Research
Issues Updates 1-10-19
Guangdong Land Holdings, Ltd.
Click Here>>

1-9-19 Canbiola, Inc. (CANB)
Canbiola, Inc. has Purchased Pure Health Products LLC and is Launching Pure Leaf Oil as its Consumer Brand

Read Complete Press Release>>

1-4-19 Endurance Exploration Group, Inc. (EXPL)
Endurance Exploration Group, Inc.
Form 15 to Terminate SEC Reporting Obligations

Click Here>>

Greenridge Global Equity Research
Issues Updates 11-6-18
Fullshare Holdings, Ltd.
Click Here>>

11-07-18 Trickle Research Initiates Research of
Alvopetro Energy, Ltd
12-24 Month Price Target $1.10

Click Here for Research Report

Trickle Research Earnings Update 11-13-18
Command Center, Inc. (CCNI)
12-24 Month Target Price $8.75

Click Here for Report

Canbiola, Inc. (CANB)

Canbiola, Inc. Uplists to OTCQB Venture Market.

Read Complete Press Release

Greenridge Global Equity Research
Issues Updates 11-2-18
Guangdong Land Holdings, Ltd.
Click Here>>

10-29 Mining Magazine

Could technology open doors to a cleaner-burning future for
coal? Clean Coal Technologies and the University of Wyoming are
collaborating on a cleaner, more efficient way for the US and the
world to produce and consume coal
Click Here for complete Article

Trickle Research issues update of
AzurRx Biopharma, Inc.  10-16-18
12-24 Month Price Target $10.25

Click Here for Update Report

10-11-18 Summit Wireless Technologies, Inc. (WISA)
Certification of Axiim Link
WiSA USB Transmitter
Read Complete Release

10-10-18 Ascendiant Capital markets, LLC
Initiates Research of
Summit Wireless Technologies, Inc. (WISA) 
  Buy Rating and Price Target $7.00

Click Here for Research Report

09-28-18 Trickle Research Initiates Research of
Summit Wireless Technologies, Inc. (WISA) 
12-24 Month Price Target $9.25

Click Here for Research Report

10-3-18, Endurance Exploration Group, Inc. (“EXPL”)

operating through its previously announced joint venture, Swordfish
Partners (the “Joint Venture”), is pleased to announce that
it has acquired title to over 600 items and artifacts
salvaged from the Steamship Pulaski.



  Black Swan Research
Research Coverage 7-18
SMM is now hosting Equity Research and updates from top tier research providers:           
   Catalyst Research  
 Trickle Research
Click here to Subscribe to Trickle Research 
 Falcon Strategic Research
 Consilium Global Research
 Click Here to Subscribe to Black Swan Research

Black Swan Newsletter



March 2019

Click here to view

Our goal with the Black Swan Connection is to provide our subscribers, investors and financial professional compatriots outstanding investment insight that is a step above and outside of what will normally be found in mainstream financial press. To that end we have brought together seasoned, successful, and some of the brightest professionals in their respective fields to provide the articles and advice that is based on decades of practice in the field.

Breaking News

Market Watch - March 18-19

Mark Cuban comes to the defense of Elon Musk and his ‘ongoing public belligerence’

Elon Musk’s “ongoing public belligerence” toward the Securities and Exchange Commission could not only weigh on the stock but also ultimately result in his removal as the boss at Tesla, JPMorgan Chase said in a note on Monday.

“The option market is embedding no volatility premium for upcoming legal events in the case of SEC v. Elon Musk,” the strategists wrote in the note. “Surprising given these fears previously caused a significant decline in Tesla TSLA, +0.26%  shares and a surge in volatility to multiyear highs.”

Fellow billionaire Mark Cuban, who had his own run-in with the SEC years ago, stepped up to defend Musk on Twitter TWTR, +0.34%  in recent days.

Read Complete Article

The thing is, if @SEC_Enforcement really cared about reducing fraud they would publish bright-line guidelines that any business person could find and understand. Then there would be no excuses. Fraud would be fraud. Instead they create regulations via litigation.

— Mark Cuban (@mcuban) March 15, 2019


This is a topic we have covered for some years. Think that Trump etc are really Draining the Swamp ?

Not so much. Like many other government institutions that have become an empire unto themselves the SEC and others wipe their backside with congressional acts, like the Jobs Act that was heralded as a way to create jobs and inspire capital formation for small business.  We plod on while the US become a second class citizen in the world of global finance.

Following was from my article in Jan-2017

From the get go the key SEC regulations are the 33 and 34 ACT’s. For you kids that means they were created in yes, 1933 and 1934.  Instituted to curtail what was then a free for all in the securities industry run by a few people who controlled all of the information. Wild speculation led to the 1929 Market crash and exacerbated a profound depression. President Roosevelt created the Securities and Exchange Commission and the 33 and 34 Act which require securities offerings to be registered and provide a structure for offerings to truthfully disclose information to investors.

From Wikipedia:

The primary purpose of the '33 Act is to ensure that buyers of securities receive complete and accurate information before they invest in securities. Unlike state blue sky laws, which impose merit reviews, the '33 Act embraces a disclosure philosophy, meaning that in theory, it is not illegal to sell a bad investment, as long as all the facts are accurately disclosed.

Sounds good in theory so what’s the problem???

First of all those acts were written 84 years ago and a lot has changed, including an amazing ability to get instant information about everything.  Instead of a new ACT that reflects changes and modern sophistication in the marketplace etc these acts have been amended and interpreted a gazillion times to the point that no one including the SEC itself can tell you what these rules mean and when they are being violated.

A good start down this rat hole is the first chapter about securities registration right from Wikipedia

Legislated pursuant to the interstate commerce clause of the Constitution, it requires that any offer or sale of securities using the means and instrumentalities of interstate commerce be registered with the SEC pursuant to the 1933 Act, unless an exemption from registration exists under the law. "Means and instrumentalities of interstate commerce" is extremely broad, and it is virtually impossible to avoid the operation of this statute by attempting to offer or sell a security without using an "instrumentality" of interstate commerce. Any use of a telephone, for example, or the mails, would probably be enough to subject the transaction to the statute.

Anybody want to tell me exactly what that means, starting with a concise explanation even of what constitutes a security????????


InvestorsHub News Wire:




Weekly Update: March 12th, 2019

Breaking News

I guess the sage of investing is a long term believer in equities.  And, why not, they have done better than any other asset class over the long term and the beauty is that you can get immediate liquidity.

Real Money March 11-19

Warren Buffett's Plan for His Wife's Inheritance Is a Must Read for Investors

In the column, Heath laid out the simple facts about long-term investing, as explained by Warren Buffett in his latest letter to shareholders. In the letter, Buffett makes a compelling case for what he calls “the American tailwind,” the simple idea that investors are not really buying companies when they invest, but an idea: that American prosperity — and the growth of its wealth — is driven by our dedication to the American idea. Over the course of roughly three human lifetimes, Buffett argues, the United States grew from just four million people to the most powerful nation on earth.

 Few people have proven smarter than Warren Buffett, so his instructions regarding his wife's eventual inheritance are worth looking in on. His instructions to the executor of his estate were very simple and quite clear. He directed that 10% of the value transferred to her should be invested in ultra-liquid, short-term Treasuries, and the other 90% be placed in a low-fee, S&P 500 Index ETF, such as Vanguard's .

Click here

1-25-19 Canbiola, Inc. (CANB)

Canbiola is Registered and Active in the GSA’s System for Award Management (SAM) and Department of Defense (DOD)

HICKSVILLE, NY, March 11, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Canbiola, Inc. (OTCQB: CANB) (“Canbiola” or the “Company”), a developer, manufacturer and seller of a variety of Cannabidiol (Hemp) based products such as oils, creams, moisturizers, chews, isolate, gel caps, and concentrate, announced today that it is now registered and active in the U.S. government GSA’s System for Award Management (SAM) and Department of Defense (DOD).

The System for Award Management (SAM) is an official website of the U.S. government. There is no cost to use SAM. GSA’s Office of Government-wide Policy is consolidating federal procurement and award systems into 1 new system—the System for Award Management (SAM). SAM is streamlining processes, improving data quality by eliminating the need to enter the same data multiple times, and consolidating hosting to save taxpayer money.

Click Here for Report


2-26-19 Trickle Research issues update of AzurRx Biopharma, Inc. (AZRX) 12-24 Month Price Target $10.25

2Today, Oppenheimer and Co. Upgraded their price target for AzurRx shares from $6 to $8. Much of the upgrade was based on two things; first, the enrolling/initiation of the cystic fibrosis trial(we have discussed that in prior research), and some telling channel checking they did amongst physicians to determine their likelihood to prescribeMS1819to their patients in the event of an approval. Obviously, given their price target bump, that polling resulted in favorable enough responses that apparently lead Oppenheimer to conclude that the drug could achieve penetration than they originally projected(they estimate 25% of the market(currently $1.2B)by 2029).

Click Here for Report

Community Search
Sign In